ALK

Allergy solutions for life

Quality of life

Under­standing allergy

ALK has an unrivalled understanding of allergens and how they affect the human body, as well as the link between allergy and respiratory diseases such as asthma.

understanding_allergy

News

  • Post date
    06/07/2019
    ALK obtains European approval for its tree SLIT-tablet against allergic rhinitis
  • Post date
    06/04/2019
    As ALK prepares to further extend their SLIT-tablet portfolio, tablet formulation is seen as key in delivering consistent positive clinical trial results
  • Post date
    06/03/2019
    Targeted early treatment with ALK’s ACARIZAX® could improve allergic asthma treatment, allergy congress hears
  • Post date
    05/13/2019
    Report on transactions with ALK-Abelló A/S B-shares and associated securities by managerial staff
  • Post date
    05/09/2019
    Three-month interim report (Q1) 2019
  • Post date
    05/02/2019
    Release date of three-month interim report 2019 for ALK and audio cast
  • Post date
    03/21/2019
    Report on transactions with ALK-Abelló A/S B-shares and associated securities by managerial staff
  • Post date
    03/21/2019
    Grant of share options and performance shares to members of the Board of Management and key employees
  • Post date
    03/13/2019
    Annual General Meeting in ALK-Abelló A/S held on 13 March 2019
ALK launches growth strategy
Transformational strategy to redefine ALK's position in the global allergy market and stimulate a new era of growth for the company.
Call for applicants
Scientists are invited to apply for the ARIA-EUFOREA Henning Løwenstein Research Award 2019.

ALK in brief

ALK at a glance
ALK is a research-driven, global pharmaceutical company focusing on allergy prevention, diagnosis and treatment. We are the foremost innovators in allergy immunotherapy – a unique treatment which reduces allergic symptoms and treats the cause of the allergy.
Global presence
ALK employs around 2,300 employees worldwide and has affiliates, production facilities and distributors around the globe. Today, around 1.5 million people worldwide use our products.
ALK's pipeline
Our development programme covers the four most important outdoor allergens in Europe, the USA and Japan (grass, birch and related trees, ragweed and Japanese cedar) and the most important indoor allergen in the world (house dust mites).
ALK's history
ALK has been at the forefront of allergy treatment for almost a century. Our story can be traced back to a small laboratory in Copenhagen, Denmark, in 1923.